Banque Cantonale Vaudoise Invests $428,000 in Illumina, Inc. (NASDAQ:ILMN)

Key Points

• Banque Cantonale Vaudoise acquired a new stake in Illumina, purchasing 5,391 shares valued at approximately $428,000 in the first quarter.
• Illumina's stock has seen ratings adjustments from several brokerages, with Barclays setting a target price of $90.00 and Morgan Stanley lowering it to $100.00, reflecting a cautious outlook on the company.
• Illumina reported earnings of $1.19 per share in its latest quarterly results, surpassing analysts' expectations, but revenue declined by 4.8% year-over-year.

Banque Cantonale Vaudoise purchased a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,391 shares of the life sciences company's stock, valued at approximately $428,000.

Other large investors also recently bought and sold shares of the company. GSA Capital Partners LLP increased its stake in Illumina by 73.3% in the first quarter. GSA Capital Partners LLP now owns 7,103 shares of the life sciences company's stock worth $564,000 after purchasing an additional 3,004 shares during the period. Federated Hermes Inc. boosted its position in Illumina by 55.4% in the 1st quarter. Federated Hermes Inc. now owns 806,759 shares of the life sciences company's stock valued at $64,008,000 after buying an additional 287,569 shares during the period. Mackenzie Financial Corp grew its stake in Illumina by 41.0% in the 1st quarter. Mackenzie Financial Corp now owns 29,886 shares of the life sciences company's stock worth $2,371,000 after acquiring an additional 8,692 shares in the last quarter. LPL Financial LLC increased its position in shares of Illumina by 10.5% during the first quarter. LPL Financial LLC now owns 91,606 shares of the life sciences company's stock worth $7,268,000 after acquiring an additional 8,739 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Illumina by 4.9% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 199,176 shares of the life sciences company's stock valued at $15,803,000 after purchasing an additional 9,252 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Wall Street Zen downgraded Illumina from a "buy" rating to a "hold" rating in a report on Saturday. Stephens restated an "overweight" rating and issued a $105.00 price target on shares of Illumina in a report on Tuesday, May 20th. Guggenheim dropped their price objective on shares of Illumina from $122.00 to $114.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Evercore ISI upped their target price on Illumina from $116.00 to $128.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Finally, Scotiabank downgraded Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price target on the stock. in a report on Friday, July 11th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Illumina has an average rating of "Hold" and an average target price of $127.47.

Insider Buying and Selling

In other Illumina news, CFO Ankur Dhingra acquired 6,100 shares of the business's stock in a transaction dated Monday, May 12th. The shares were purchased at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the purchase, the chief financial officer directly owned 24,906 shares of the company's stock, valued at $2,022,616.26. The trade was a 32.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.17% of the company's stock.

Illumina Stock Performance

Shares of NASDAQ ILMN traded up $3.78 during mid-day trading on Monday, hitting $98.44. The stock had a trading volume of 2,360,354 shares, compared to its average volume of 2,418,604. The firm has a market cap of $15.58 billion, a PE ratio of 12.46, a PEG ratio of 1.75 and a beta of 1.37. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The company has a 50 day moving average of $93.80 and a two-hundred day moving average of $92.28. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.17. The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%. The company's revenue was down 4.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.36 earnings per share. Research analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.